GSK-872

Research use only, not for human use.

GSK-872 (GSK 872) is a potent and selective RIPK3 (receptor-interacting protein kinase-3) inhibitor.

GSK-872 (GSK'872) is a potent and selective RIPK3 (receptor-interacting protein kinase-3) inhibitor; interferes with receptor-mediated endocytosis, entry of HIV, and synaptic vesicle recycling; attenuates rat nucleus pulposus (NP) cells death.(In Vitro):GSK-872 (GSK'872; 0.01-3 μM; 24 hours) blocks TNF-induced necroptosis in human HT-29 cells in a concentration-dependent manner.(In Vivo):GSK-872 (25 mM; intracerebroventricular injection) can attenuate brain edema and improve neurological function following subarachnoid hemorrhage (SAH) and reduce the number of necrotic cells. GSK-872 can also decrease the protein levels of RIPK3 and MLKL, and cytoplasmic translocation and expression of HMGB1, an important pro-inflammatory protein.

Cell Viability Assay Cell Line:HT-29 cells Concentration:0.01, 0.03 , 0.1, 0.3, 1, and 3 μM Incubation Time:24 hours Result:Blocked TNF-induced necroptosis in a concentration-dependent manner.

Animal Model:Eight weeks old Sprague-Dawley male rats with 300-320 g body weight (rat SAH model)Dosage:25 mM/6 μL Administration:Syringe pump (intracerebroventricular) at 30 min after SAH Result:Attenuated brain edema, improved neurological function and decreased the number of necrotic cells in the ipsilateral cortex. Decreased the expression of RIPK3, MLKL and cytoplasmic HMGB1 at 72 h after SAH in the ipsilateral cortex.

GSK 872

Apoptosis

RIP kinase

RIP3K

——

——

1346546-69-7

383.49

C19H17N2O2S2

>98% (HPLC)

DMSO: 71 mg/mL (185.1 mM); Ethanol: 38 mg/mL (99.1 mM); Water: <1 mg/mL （ < 1 mg/ml refers to the product slightly soluble or insoluble )

O=S(C1=CC=C2N=CC=C(NC3=CC=C(SC=N4)C4=C3)C2=C1)(C(C)C)=O

N-5-benzothiazolyl-6-[(1-methylethyl)sulfonyl]-4-quinolinamine

(-20℃)

With Ice Pack

≥ 2 years